December 26, 2017 / 7:19 AM / a month ago

BRIEF-Nanobiotix: FDA Approves First Immuno-Oncology Trial

Dec 26 (Reuters) - NANOBIOTIX SA:

* NANOBIOTIX : FDA APPROVES NANOBIOTIX‘S FIRST IMMUNO-ONCOLOGY TRIAL

* ‍FIRST NANOBIOTIX IMMUNO-ONCOLOGY TRIAL WILL BE CONDUCTED IN U.S.​

* ‍MULTI-ARM TRIAL TARGETS SUB-POPULATION OF ADVANCED AND METASTATIC LUNG (NSCLC), AND HEAD AND NECK CANCER PATIENTS (HNSCC)​

* ‍FIRST PATIENT VISIT IN TRIAL IS EXPECTED IN Q2 2018​

* ‍FIRST EXPECTED RESULTS IN SUMMER OF 2019.​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below